Roche Holding AGXSWX:ROP -0.26%77 5-Year Yield-on-Cost % is 3.12 as of Jul. 06, 2026, which is 10% below its 10-year median of 3.46. GuruFocus rates XSWX:ROP with a GF Score™ of 77/100 and a GF Value™ of CHF264.65 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 517 Drug Manufacturers companies, Roche Holding AG ranks better than 57.83% on this metric.
Roche Holding AG's yield on cost for the quarter that ended in Dec. 2025 was 3.12.
The historical rank and industry rank for Roche Holding AG's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:ROP'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.47 Med: 3.46 Max: 4.73
Current: 3.12
During the past 13 years, Roche Holding AG's highest Yield on Cost was 4.73. The lowest was 2.47. And the median was 3.46.
XSWX:ROP's 5-Year Yield-on-Cost % is ranked better than 57.83% of 517
companies
in the Drug Manufacturers industry
Industry Median: 2.26
vs XSWX:ROP: 3.12
Roche Holding AG (XSWX:ROP) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Roche Holding AG 5-Year Yield-on-Cost % Related Terms
XSWX:ROP vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's 5-Year Yield-on-Cost % falls into.
Roche Holding AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Roche Holding AG (XSWX:ROP) has a 5-Year Yield-on-Cost % of 3.12 as of Jul. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Roche Holding AG and its competitors. This is 10% below median its historical median of 3.46. Over the past decade, Roche Holding AG's 5-Year Yield-on-Cost % has ranged from 2.47 to 4.73. According to the industry distribution chart, Roche Holding AG ranks #218 out of 517 companies in the Drug Manufacturers industry, placing it in the top 42.2%.
Is Roche Holding AG's 5-Year Yield-on-Cost % too high?
Roche Holding AG's current 5-Year Yield-on-Cost % of 3.12 is 10% below median its 10-year median of 3.46. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 4.73. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.26. Roche Holding AG's value of 3.12 is 38.1% above this industry median. Based on the distribution chart, Roche Holding AG ranks #218 out of 517 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #218 out of 517 companies for 5-Year Yield-on-Cost %. This puts Roche Holding AG in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.26. Roche Holding AG's value of 3.12 is 38.1% above this benchmark. Historically, Roche Holding AG's own 5-Year Yield-on-Cost % has ranged from 2.47 to 4.73 over the past decade. While the company's 10-year median is 3.46 vs. the industry median of 2.26, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.26, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current 5-Year Yield-on-Cost % of 3.12 is 38.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current 5-Year Yield-on-Cost % is 3.12, which is 10% below median its own 10-year median of 3.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.65, compared to a current price of CHF340.60 — trading 28.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 3.12, which is 10% below median its 10-year median of 3.46 and 38.1% above the Drug Manufacturers industry median of 2.26. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current 5-Year Yield-on-Cost % is 3.12 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF340.60 is trading 28.7% above its estimated GF Value™ of CHF264.65.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
5-Year Yield-on-Cost %: 3.12 (10% below median its 10-year median of 3.46)
GF Value™: CHF264.65 vs. price of CHF340.60 (28.7% above fair value)
Industry Position: 38.1% above the Drug Manufacturers median (#218 of 517)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score
Get the complete analysis for XSWX:ROP
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 